Improved enrichment of circulating tumor cells from diagnostic leukapheresis product

Abstract

AbstractThe median number of circulating tumor cells (CTCs) detected in 7.5 mL of peripheral blood by CellSearch (PB‐CS) in patients with metastatic prostate cancer is in the order of 1–10, which means many samples have insufficient tumor cells for comprehensive characterization. A significant increase is obtained through diagnostic leukapheresis (DLA), however, only 2%–3% of the DLA product can be processed per CellSearch test, limiting the gain. We processed aliquots from 30 DLA products of metastatic prostate cancer patients consisting of 0.2 × 109 leukocytes using CellSearch (DLA‐CS) as well as the newly introduced reduced enrichment reagent protocol (RER), which uses 10‐fold less enrichment reagents than DLA‐CS. The number of tumor cells and the total number of captured cells were determined using the CellTracks Analyzer. Additionally, for six DLA samples, a 1.0 × 109 leukocyte aliquot was processed (RER+), using twofold less enrichment reagents than DLA‐CS. A median 2.7‐fold reduction in leukocyte co‐enrichment was found between DLA‐CS and RER methods without any loss in tumor cell recovery (Wilcoxon Signed Ranks Test, p = 0.953). Using 1.0 × 109 leukocyte aliquots a fourfold increase in tumor cells was found compared to DLA‐CS and a 19‐fold increase compared to PB‐CS was obtained. The here‐introduced RER protocol results in a higher final sample purity without any loss in tumor cell recovery while using 10‐fold less CellSearch capture reagent. With this improved method, 26% of the leukapheresis sample can now be processed using reagents from a single CellSearch test, enabling the obtainment of a sufficient number of CTCs for comprehensive characterization in most metastatic prostate cancer patients.